Bryn Mawr Capital Management LLC Purchases 31,266 Shares of Becton, Dickinson and Company (NYSE:BDX)

Bryn Mawr Capital Management LLC increased its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 349.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,205 shares of the medical instruments supplier's stock after acquiring an additional 31,266 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Becton, Dickinson and Company were worth $9,209,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 64.0% in the 1st quarter. Larson Financial Group LLC now owns 2,391 shares of the medical instruments supplier's stock valued at $548,000 after purchasing an additional 933 shares during the period. Violich Capital Management Inc. raised its position in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Violich Capital Management Inc. now owns 21,514 shares of the medical instruments supplier's stock worth $4,928,000 after buying an additional 250 shares in the last quarter. PAX Financial Group LLC boosted its stake in Becton, Dickinson and Company by 6.9% during the first quarter. PAX Financial Group LLC now owns 997 shares of the medical instruments supplier's stock valued at $228,000 after buying an additional 64 shares during the period. Wealthfront Advisers LLC increased its stake in Becton, Dickinson and Company by 53.2% in the 1st quarter. Wealthfront Advisers LLC now owns 7,960 shares of the medical instruments supplier's stock worth $1,823,000 after acquiring an additional 2,764 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Becton, Dickinson and Company by 7.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 7,537 shares of the medical instruments supplier's stock worth $1,726,000 after acquiring an additional 503 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Down 0.0%

BDX traded down $0.08 during trading on Wednesday, hitting $178.23. 4,159,475 shares of the stock traded hands, compared to its average volume of 2,125,967. The firm has a market capitalization of $51.08 billion, a P/E ratio of 34.01, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The firm has a 50-day moving average of $173.02 and a 200 day moving average of $205.02.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business posted $3.17 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.33%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BDX shares. Morgan Stanley cut their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Barclays cut their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research report on Thursday, May 1st. Finally, Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of "Hold" and a consensus target price of $219.22.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.